1. Home
  2. BXMT vs AUPH Comparison

BXMT vs AUPH Comparison

Compare BXMT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Mortgage Trust Inc.

BXMT

Blackstone Mortgage Trust Inc.

HOLD

Current Price

$13.93

Market Cap

2.5B

Sector

Real Estate

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

N/A

Current Price

$16.51

Market Cap

2.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BXMT
AUPH
Founded
1966
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.1B
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
BXMT
AUPH
Price
$13.93
$16.51
Analyst Decision
Buy
Buy
Analyst Count
5
4
Target Price
$21.38
$17.25
AVG Volume (30 Days)
2.7M
1.2M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
9.85%
N/A
EPS Growth
154.70
5075.00
EPS
N/A
0.53
Revenue
N/A
$283,055,000.00
Revenue This Year
N/A
$17.54
Revenue Next Year
N/A
$15.74
P/E Ratio
N/A
$31.60
Revenue Growth
N/A
20.38
52 Week Low
$13.73
$10.34
52 Week High
$20.67
$19.25

Technical Indicators

Market Signals
Indicator
BXMT
AUPH
Relative Strength Index (RSI) 32.23 57.03
Support Level $13.73 $14.67
Resistance Level $14.84 $19.25
Average True Range (ATR) 0.32 0.55
MACD 0.07 0.16
Stochastic Oscillator 12.37 56.02

Price Performance

Historical Comparison
BXMT
AUPH

About BXMT Blackstone Mortgage Trust Inc.

Blackstone Mortgage Trust Inc is an externally managed real estate finance company that originates, acquires, and manages senior loans and other debt or credit-oriented investments collateralized by or relating to commercial real estate in North America, Europe, and Australia. Its portfolio is composed of senior loans secured by high-quality, institutional assets located in main markets, and sponsored by experienced, well-capitalized real estate investment owners and operators. The group finances its investments in a variety of ways, including borrowing under secured credit facilities, issuing collateralized loan obligations, or CLOs, other securitization transactions, syndicating senior loans and/or participations, and other forms of asset-level financing.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: